About RiboBio
RiboBio is a Healthcare company based in Guangzhou (China) founded in 2004. Developer of oligonucleotides. RiboBio has raised $40 million across 1 funding round from investors including SANY Group and Panlin Capital. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Drug Development. Its competitors include Sino Biological and Sangon Biotech; 2 of its 2 listed competitors have raised funding.
Company details
Founded in 2004 and based in Guangzhou, China, oligonucleotides are developed by RiboBio within the biotechnology sector. A GMP-approved manufacturing facility is operated for production, alongside process development services. RD offerings encompass RNAimiRNA functional studies, high-throughput screens for RNAi and small molecules, and microarray analysis for mRNA and miRNA. A proprietary solid-phase synthesis process for RNA oligonucleotides has been established.
- Headquarters Guangzhou, China
- SectorsHealthcare
- Phoneβ’β’β’β’ β’β’β’β’
- Website ribobio.com
- Social LinkedIn
- Total Equity Funding$40M (USD)
in 1 rounds
- Latest Funding Round$40M (USD), Series E
Jul 2022
- InvestorsSANY Group
& 1 more
Funding Insights of RiboBio
RiboBio has successfully raised a total of $40M through 1 strategic funding round. The most recent funding activity was a Series E round of $40 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $40M
- Total Rounds 1
- Last Round Series E β $40M
- First Round $40M
(Jul 2022)
- Investors Count 2
All 1 funding rounds of RiboBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2022 | $40M | Series E | β | Panlin Capital |
2 investors in total: 2 institutional.
Investors in RiboBio
RiboBio has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include SANY Group and Panlin Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| panlincap.com | ||||
Manufacturer of construction & mining equipment, port, and oil drilling machinery | 1989 | sanyglobal.com | Changsha, China |
Investor details for RiboBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of RiboBio
2 dated milestones of RiboBio across 18 years, from founding to its latest funding, stage changes and deals.
- Founded RiboBio is founded.
- Funding First funding round of $40.0M.
Competitors of RiboBio
RiboBio has 2 listed competitors in our database, 2 of them funded. They include Sino Biological and Sangon Biotech.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sinobiological.com | 2007 | Beijing, China | $29.41M | Reagents and kits are provided for clinical research applications. | ||
| sangon.com | 2003 | Shanghai, China | $300M | Research services, reagents, and kits for biotech applications are provided. |
Detailed competitors of RiboBio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of RiboBio
Websites that share an audience with RiboBio (ribobio.com).
Websites whose visitors overlap most with RiboBio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
uptbio.com | uptbio.com | 100% | #9,568,018 | β | |
| shbiochip.com | 78% | View details | |||
| sangon.com | 77% | 226.9K | #101,937 | View details | |
beyotime.com | beyotime.com | 77% | β | ||
thermofisher.cn | thermofisher.cn | 38% | #53,435 | β |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ribobio
Complete news archive for RiboBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RiboBio
RiboBio was founded in 2004 and raised its 1st funding round 18 years after it was founded.
RiboBio is headquartered in Guangzhou, China. It is registered at Guangzhou, Guangdong, China.
RiboBio is a funded company, having raised a total of $40M across 1 funding round to date. The company's 1st funding round was a Series E of $40M, raised on Jul 2022.
Founded in 2004 and based in Guangzhou, China, oligonucleotides are developed by RiboBio within the biotechnology sector. A GMP-approved manufacturing facility is operated for production, alongside process development services. RD offerings encompass RNAimiRNA functional studies, high-throughput screens for RNAi and small molecules, and microarray analysis for mRNA and miRNA. A proprietary solid-phase synthesis process for RNA oligonucleotides has been established.
RiboBio's top competitors include Sino Biological and Sangon Biotech.
RiboBio has 2 investors. Key investors include SANY Group, and Panlin Capital.

